PT  - JOURNAL ARTICLE
AU  - Denning, David W
TI  - Antifungal drug resistance: an update
AID  - 10.1136/ejhpharm-2020-002604
DP  - 2022 Mar 01
TA  - European Journal of Hospital Pharmacy
PG  - 109--112
VI  - 29
IP  - 2
4099  - http://ejhp.bmj.com/content/29/2/109.short
4100  - http://ejhp.bmj.com/content/29/2/109.full
SO  - Eur J Hosp Pharm2022 Mar 01; 29
AB  - The number of antifungal classes is small, and resistance is becoming a much more frequent problem. Much greater emphasis needs to be placed on susceptibility testing and antifungal stewardship. Such efforts demonstrably improve survival and overall clinical outcomes. Positively diagnosing a fungal infection with laboratory markers often allows antibacterial therapy to be stopped (ie, anti-tuberculous therapy in chronic pulmonary aspergillosis or antibiotics other than cotrimoxazole in Pneumocystis pneumonia), contributing to antimicrobial resistance control generally. Non-culture based diagnostics for fungal disease are transformational in terms of sensitivity and speed, but only occasionally identify antifungal resistance.No data are available. No specific new data.